Biology-driven therapy

With the goal of “turning mechanisms of disease into mechanisms of therapy” by integrating newly developed diagnostic and therapeutic reagents for proof of concept studies (target validation) and clinical trials (reverse translation), this program constitutes an indispensable element in the translational chain to transfer novel knowledge from target identification and characterization to its exploitation in clinical trials. It includes structure-guided drug design and molecularly targeted therapies with immunotherapies including cellular therapies. The program focuses on rational drug design for newly identified and characterized targets by NMR-based, virtual or medium-throughput screenings followed by lead optimization via medicinal chemistry and is complementary to drug development in industry due to its close integration into a clinical framework. Great progress has been made in the complementary development of advanced immunotherapy approaches and medicinal products that make cellular approaches more efficient, more specific and safer.